Eli Lilly Reports Positive TRIUMPH-1 Trial Results for Retatrutide
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 35 minutes ago
0mins
Source: PRnewswire
- Significant Weight Loss: In the TRIUMPH-1 trial, participants receiving 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, with 45.3% achieving ≥30% weight loss, indicating the drug's potential in obesity treatment.
- Sustained Long-Term Weight Loss: Participants with a baseline BMI ≥35 who continued on 12 mg retatrutide for 104 weeks achieved an average weight loss of 85.0 lbs (30.3%), demonstrating the drug's efficacy and safety in long-term use.
- Multiple Health Improvements: All doses of retatrutide met primary and key secondary endpoints at 80 weeks, with significant improvements in cardiovascular health metrics, including waist circumference, non-HDL cholesterol, and systolic blood pressure, highlighting its positive impact on overall health.
- High Patient Acceptance: In the 12 mg group, 65.3% of participants achieved a BMI <30 at 80 weeks, showcasing the drug's effectiveness in weight loss and improvement of obesity-related health issues, potentially making it a vital tool for future obesity treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1021.410
Low
950.00
Averages
1192
High
1500
Current: 1021.410
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Next-Gen Obesity Drug Trial Success
- Significant Weight Loss: Eli Lilly's retatrutide achieved an average weight loss of 28.3%, or 70.3 pounds, in a Phase 3 trial with 2,500 patients, indicating its potential to become a leading product in the obesity treatment market.
- Broad Market Potential: Analysts project that retatrutide could generate sales of $3.8 billion by 2030, highlighting its strategic importance in the rapidly growing weight loss and diabetes drug market, particularly in competition with Novo Nordisk.
- Good Safety Profile: While 42% of patients on the highest dose experienced nausea, the safety data were consistent with other GLP-1 medications, and the lower dose group had a lower discontinuation rate due to side effects compared to placebo, indicating excellent tolerability.
- Market Share Maintenance: Eli Lilly holds a 60.1% share of the U.S. obesity and diabetes drug market, compared to Novo Nordisk's 39.4%, and the success of retatrutide will further solidify Lilly's market leadership, especially as Novo's new drug is still in early development stages.
See More
Eli Lilly Reports Positive TRIUMPH-1 Trial Results for Retatrutide
- Significant Weight Loss: In the TRIUMPH-1 trial, participants receiving 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, with 45.3% achieving ≥30% weight loss, indicating the drug's potential in obesity treatment.
- Sustained Long-Term Weight Loss: Participants with a baseline BMI ≥35 who continued on 12 mg retatrutide for 104 weeks achieved an average weight loss of 85.0 lbs (30.3%), demonstrating the drug's efficacy and safety in long-term use.
- Multiple Health Improvements: All doses of retatrutide met primary and key secondary endpoints at 80 weeks, with significant improvements in cardiovascular health metrics, including waist circumference, non-HDL cholesterol, and systolic blood pressure, highlighting its positive impact on overall health.
- High Patient Acceptance: In the 12 mg group, 65.3% of participants achieved a BMI <30 at 80 weeks, showcasing the drug's effectiveness in weight loss and improvement of obesity-related health issues, potentially making it a vital tool for future obesity treatment.
See More
Novo Nordisk and Eli Lilly's Price Cuts Attract Patients to Weight-Loss Pills
- Price Reduction Impact: Novo Nordisk's oral Wegovy and Eli Lilly's Foundayo are priced lower than their injectable counterparts at approximately $149 per month, prompting patients to switch to branded medications, thereby enhancing both companies' competitive positions in the weight-loss drug market.
- Patient Switching Trend: Doctors report an increasing number of patients transitioning from compounded medications to branded drugs, particularly Wegovy, due to its strong brand recognition and established heart-protective data, which boosts patient confidence in its efficacy.
- Insurance Coverage Challenges: Despite the price reductions, insurance coverage remains a significant barrier, with many patients facing denials from insurers, leading doctors to express hope that the upcoming government program will alleviate these issues and expand access.
- Market Expansion Potential: The introduction of oral medications is expanding the GLP-1 market, with physicians noting that many patients who previously declined due to cost are now eager to try these drugs, indicating promising growth opportunities in the future.
See More
Intense Competition in Weight-Loss Drug Market
- Market Leadership Shift: While Novo Nordisk was the first to launch GLP-1 weight-loss drugs, production issues have led to phenomenal sales growth of 125% for Eli Lilly's Mounjaro and 80% for Zepbound in Q1 2026, highlighting intense market competition.
- Drug Efficacy Comparison: Novo Nordisk's Wagovy pill has shown strong uptake, attracting new customers despite facing pricing pressures and patent expirations, with a P/E ratio of 10x indicating long-term growth potential.
- High-Risk Investment Opportunity: Viking Therapeutics, a money-losing startup with GLP-1 drugs in clinical trials, has seen dramatic price swings but negligible growth over the past year, suggesting that a breakthrough could lead to significant share price increases, appealing to aggressive investors.
- Investment Strategy Recommendations: For those seeking a balance of risk and reward, Novo Nordisk may be the best choice, while Eli Lilly leverages its leadership position to diversify its drug pipeline, and Viking presents a high-risk potential wildcard.
See More
Investment Opportunities in the GLP-1 Drug Market
- Industry Leader: Eli Lilly's GLP-1 drugs Mounjaro and Zepbound saw sales increase by 125% and 80% respectively in Q1 2026, demonstrating strong performance in the weight-loss drug market, although its high P/E ratio of 35x raises concerns, yet investors remain optimistic about future growth.
- Novo Nordisk's Comeback: The launch of Novo Nordisk's Wagovy pill has been well-received, attracting many new customers despite facing pricing pressures and patent expirations; its appealing P/E ratio of 10x may present a turnaround opportunity for value-focused investors.
- Risky Investment Choice: Viking Therapeutics, a startup with GLP-1 drugs in clinical trials, has experienced significant stock price volatility without substantial growth, but a breakthrough could lead to a material price increase, making it suitable for aggressive growth investors.
- Market Diversification: In the GLP-1 drug sector, Eli Lilly and Novo Nordisk each have their strengths, with the former expanding its drug pipeline while the latter may attract more investor interest due to its pricing advantages and market potential.
See More
Investment Opportunities in the GLP-1 Drug Market
- Eli Lilly Market Leadership: Eli Lilly's GLP-1 injections, Mounjaro and Zepbound, saw sales increase by 125% and 80% respectively in Q1 2026, indicating strong demand in the weight-loss drug market; despite sluggish uptake of its newly introduced GLP-1 pill, it remains a leading player in the industry.
- Novo Nordisk's Comeback Potential: Novo Nordisk's GLP-1 pill shares the same active ingredient as its injection, leading to high market acceptance; although facing pricing pressures and patent expirations, its stock is down 45% from its 52-week high, presenting a potential turnaround opportunity for value investors.
- High-Risk Investment in Viking Therapeutics: Viking Therapeutics, a startup with GLP-1 drugs in clinical trials, has experienced dramatic stock price swings without significant growth; however, a breakthrough could lead to substantial share price increases, making it suitable for aggressive growth investors.
- Diverse Investment Options: In the GLP-1 drug market, Novo Nordisk is seen as the best balance of risk and reward, while Eli Lilly leverages its market leadership to diversify its drug pipeline; Viking Therapeutics could be a wildcard for high-risk investors.
See More
Eli Lilly's Next-Gen Obesity Drug Trial Success
- Significant Weight Loss: Eli Lilly's retatrutide achieved an average weight loss of 28.3%, or 70.3 pounds, in a Phase 3 trial with 2,500 patients, indicating its potential to become a leading product in the obesity treatment market.
- Broad Market Potential: Analysts project that retatrutide could generate sales of $3.8 billion by 2030, highlighting its strategic importance in the rapidly growing weight loss and diabetes drug market, particularly in competition with Novo Nordisk.
- Good Safety Profile: While 42% of patients on the highest dose experienced nausea, the safety data were consistent with other GLP-1 medications, and the lower dose group had a lower discontinuation rate due to side effects compared to placebo, indicating excellent tolerability.
- Market Share Maintenance: Eli Lilly holds a 60.1% share of the U.S. obesity and diabetes drug market, compared to Novo Nordisk's 39.4%, and the success of retatrutide will further solidify Lilly's market leadership, especially as Novo's new drug is still in early development stages.
See More
Eli Lilly Reports Positive TRIUMPH-1 Trial Results for Retatrutide
- Significant Weight Loss: In the TRIUMPH-1 trial, participants receiving 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, with 45.3% achieving ≥30% weight loss, indicating the drug's potential in obesity treatment.
- Sustained Long-Term Weight Loss: Participants with a baseline BMI ≥35 who continued on 12 mg retatrutide for 104 weeks achieved an average weight loss of 85.0 lbs (30.3%), demonstrating the drug's efficacy and safety in long-term use.
- Multiple Health Improvements: All doses of retatrutide met primary and key secondary endpoints at 80 weeks, with significant improvements in cardiovascular health metrics, including waist circumference, non-HDL cholesterol, and systolic blood pressure, highlighting its positive impact on overall health.
- High Patient Acceptance: In the 12 mg group, 65.3% of participants achieved a BMI <30 at 80 weeks, showcasing the drug's effectiveness in weight loss and improvement of obesity-related health issues, potentially making it a vital tool for future obesity treatment.
See More
Novo Nordisk and Eli Lilly's Price Cuts Attract Patients to Weight-Loss Pills
- Price Reduction Impact: Novo Nordisk's oral Wegovy and Eli Lilly's Foundayo are priced lower than their injectable counterparts at approximately $149 per month, prompting patients to switch to branded medications, thereby enhancing both companies' competitive positions in the weight-loss drug market.
- Patient Switching Trend: Doctors report an increasing number of patients transitioning from compounded medications to branded drugs, particularly Wegovy, due to its strong brand recognition and established heart-protective data, which boosts patient confidence in its efficacy.
- Insurance Coverage Challenges: Despite the price reductions, insurance coverage remains a significant barrier, with many patients facing denials from insurers, leading doctors to express hope that the upcoming government program will alleviate these issues and expand access.
- Market Expansion Potential: The introduction of oral medications is expanding the GLP-1 market, with physicians noting that many patients who previously declined due to cost are now eager to try these drugs, indicating promising growth opportunities in the future.
See More
Intense Competition in Weight-Loss Drug Market
- Market Leadership Shift: While Novo Nordisk was the first to launch GLP-1 weight-loss drugs, production issues have led to phenomenal sales growth of 125% for Eli Lilly's Mounjaro and 80% for Zepbound in Q1 2026, highlighting intense market competition.
- Drug Efficacy Comparison: Novo Nordisk's Wagovy pill has shown strong uptake, attracting new customers despite facing pricing pressures and patent expirations, with a P/E ratio of 10x indicating long-term growth potential.
- High-Risk Investment Opportunity: Viking Therapeutics, a money-losing startup with GLP-1 drugs in clinical trials, has seen dramatic price swings but negligible growth over the past year, suggesting that a breakthrough could lead to significant share price increases, appealing to aggressive investors.
- Investment Strategy Recommendations: For those seeking a balance of risk and reward, Novo Nordisk may be the best choice, while Eli Lilly leverages its leadership position to diversify its drug pipeline, and Viking presents a high-risk potential wildcard.
See More
Investment Opportunities in the GLP-1 Drug Market
- Industry Leader: Eli Lilly's GLP-1 drugs Mounjaro and Zepbound saw sales increase by 125% and 80% respectively in Q1 2026, demonstrating strong performance in the weight-loss drug market, although its high P/E ratio of 35x raises concerns, yet investors remain optimistic about future growth.
- Novo Nordisk's Comeback: The launch of Novo Nordisk's Wagovy pill has been well-received, attracting many new customers despite facing pricing pressures and patent expirations; its appealing P/E ratio of 10x may present a turnaround opportunity for value-focused investors.
- Risky Investment Choice: Viking Therapeutics, a startup with GLP-1 drugs in clinical trials, has experienced significant stock price volatility without substantial growth, but a breakthrough could lead to a material price increase, making it suitable for aggressive growth investors.
- Market Diversification: In the GLP-1 drug sector, Eli Lilly and Novo Nordisk each have their strengths, with the former expanding its drug pipeline while the latter may attract more investor interest due to its pricing advantages and market potential.
See More
Investment Opportunities in the GLP-1 Drug Market
- Eli Lilly Market Leadership: Eli Lilly's GLP-1 injections, Mounjaro and Zepbound, saw sales increase by 125% and 80% respectively in Q1 2026, indicating strong demand in the weight-loss drug market; despite sluggish uptake of its newly introduced GLP-1 pill, it remains a leading player in the industry.
- Novo Nordisk's Comeback Potential: Novo Nordisk's GLP-1 pill shares the same active ingredient as its injection, leading to high market acceptance; although facing pricing pressures and patent expirations, its stock is down 45% from its 52-week high, presenting a potential turnaround opportunity for value investors.
- High-Risk Investment in Viking Therapeutics: Viking Therapeutics, a startup with GLP-1 drugs in clinical trials, has experienced dramatic stock price swings without significant growth; however, a breakthrough could lead to substantial share price increases, making it suitable for aggressive growth investors.
- Diverse Investment Options: In the GLP-1 drug market, Novo Nordisk is seen as the best balance of risk and reward, while Eli Lilly leverages its market leadership to diversify its drug pipeline; Viking Therapeutics could be a wildcard for high-risk investors.
See More
